SummaryRMgm-4478
|
Successful modification | The parasite was generated by the genetic modification |
The mutant contains the following genetic modification(s) | Gene mutation |
Reference (PubMed-PMID number) |
Reference 1 (PMID number) : 30011270 |
MR4 number | |
top of page | |
Parent parasite used to introduce the genetic modification | |
Rodent Malaria Parasite | P. berghei |
Parent strain/line | P. berghei ANKA |
Name parent line/clone | Not applicable |
Other information parent line | |
top of page | |
The mutant parasite was generated by | |
Name PI/Researcher | Douglas RG, Frischknecht F |
Name Group/Department | Integrative Parasitology, Center for Infectious Diseases |
Name Institute | Heidelberg University Medical School |
City | Heidelberg |
Country | Germany |
top of page | |
Name of the mutant parasite | |
RMgm number | RMgm-4478 |
Principal name | Actin-1 recipient line |
Alternative name | |
Standardized name | |
Is the mutant parasite cloned after genetic modification | Yes |
top of page | |
Phenotype | |
Asexual blood stage | Not different from wild type |
Gametocyte/Gamete | Not different from wild type |
Fertilization and ookinete | Not different from wild type |
Oocyst | Not different from wild type |
Sporozoite | Not different from wild type |
Liver stage | Not different from wild type |
Additional remarks phenotype | Mutant/mutation This mutant is used as a 'actin-1' recipient line for introduction of mutated forms of actin-1. Constructs to integrate mutated forms of actin 1 integrate by double homologous integration at the 5'- and 3'-UTR regions of actin-1 thereby replacing the wild type copy of actin 1 and the yfcu::hdfr selection cassette. These mutants are selected by negative selection using 5-FC Analyses of these mutant provided evidence for: 'modification of most subunit–subunit interaction sites of actin-1 was lethal, whereas changes in actin subdomains 1 and 4 reduced efficient sporozoite motility (and hence mosquito organ penetration). The strong penetration defects could be rescued by over-expression of the actin filament regulator coronin. Through these comparative approaches we identified an essential and common contributor, subdomain 3, which drives the differential dynamic behaviour of two highly divergent eukaryotic actins in motile cells.' Other mutants |
top of page | |||||||||||||||||||||||||||
Details of the target gene | |||||||||||||||||||||||||||
Gene Model of Rodent Parasite | PBANKA_1459300 | ||||||||||||||||||||||||||
Gene Model P. falciparum ortholog | PF3D7_1246200 | ||||||||||||||||||||||||||
Gene product | actin I | ||||||||||||||||||||||||||
Gene product: Alternative name | ACT1; actin1 | ||||||||||||||||||||||||||
top of page | |||||||||||||||||||||||||||
Details of the genetic modification | |||||||||||||||||||||||||||
Short description of the mutation | wild type actin 1 under control 3'-UTR dhfs and yfcu::hdhfr in locus | ||||||||||||||||||||||||||
Inducable system used | No | ||||||||||||||||||||||||||
Short description of the conditional mutagenesis | Not available | ||||||||||||||||||||||||||
Additional remarks inducable system | |||||||||||||||||||||||||||
Type of plasmid/construct | (Linear) plasmid double cross-over | ||||||||||||||||||||||||||
PlasmoGEM (Sanger) construct/vector used | No | ||||||||||||||||||||||||||
Modified PlasmoGEM construct/vector used | No | ||||||||||||||||||||||||||
Plasmid/construct map | |||||||||||||||||||||||||||
Plasmid/construct sequence | |||||||||||||||||||||||||||
Restriction sites to linearize plasmid | |||||||||||||||||||||||||||
Selectable marker used to select the mutant parasite | hdhfr/yfcu | ||||||||||||||||||||||||||
Promoter of the selectable marker | eef1a | ||||||||||||||||||||||||||
Selection (positive) procedure | pyrimethamine | ||||||||||||||||||||||||||
Selection (negative) procedure | No | ||||||||||||||||||||||||||
Additional remarks genetic modification | For the generation of a recipient line, the endogenous actin 1 gene containing silent restriction sites to facilitate subdomain exchanges were ordered from GeneArt (Invitrogen Corp) and cloned into the Pb238 vector with BamHI and XbaI restriction sites. The actin 5′ untranslated region (UTR) was amplified using primers 1 and 2 and cloned into the vector using restriction enzymes SalI and XbaI. The flanking actin 3′ UTR was amplified using primers 3 and 4 and cloned into the transfection vector via AvrII and KpnI restriction sites. The 3′ UTR of dihydrofolate synthase (dhfs) was cloned from another vector [87] into the downstream region of the actin ORF using BamHI and EcoRV restriction enzymes. Finally the positive-negative selection cassette hdhfr-yfcu (standing for human dihydrofolate reductase, yeast cytosine deaminase and uridyl phosphoribosyl transferase fusion enzyme)replaced the original selection cassette using primers 5 and 6 and restriction enzymes EcoRV and AvrII. Linearisation of the construct was achieved through SalI and PmeI digestion, followed by DNA isolation using ethanol precipitation. Transfections were then performed as described previously and positively selected using pyrimethamine (0.07 mg/mL) to yield a recipient line. | ||||||||||||||||||||||||||
Additional remarks selection procedure | |||||||||||||||||||||||||||
| |||||||||||||||||||||||||||
top of page |